Merck, Eisai to discontinue late-stage study for skin cancer
(Reuters) -Merck & Co Inc and Eisai Co Ltd said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival. The decision to discontinue the trial was based on the recommendation of an independent data monitoring committee after an interim analysis, the companies said. Improvement in overall survival […]